Literature DB >> 18317360

Increased immunostimulatory activity conferred to antigen-presenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation.

Alessandro Zerbini1, Massimo Pilli, Francesco Fagnoni, Guido Pelosi, Maria Grazia Pizzi, Simona Schivazappa, Diletta Laccabue, Cristina Cavallo, Claudia Schianchi, Carlo Ferrari, Gabriele Missale.   

Abstract

Radiofrequency thermal ablation represents an effective treatment for hepatocellular carcinoma (HCC) and it can also exert an "adjuvant" effect on spontaneous antitumor T-cell responses, as suggested by human and animal studies. The adjuvant effect is thought to depend on the huge amount of necrotic tumor antigen made available to the immune system by HCC thermal ablation. In addition, radiofrequency thermal ablation may result in the release of local stimuli responsible for activation and maturation of antigen-presenting cells (APCs). To test this hypothesis, we studied APC maturation and function in 19 patients undergoing thermal ablation for HCC. Patients' monocytes induced to differentiate with granulocyte macrophage colony-stimulating factor (GM-CSF), or GM-CSF plus IL-4, were cocultured in vitro with tumor debris generated by radiofrequency thermal ablation. Expression of costimulatory molecules, lymphnode homing chemokine receptor, antigen presentation, and cytokine secretion were enhanced by incubation with HCC treated tissue as compared with untreated HCC and nontumor liver tissue. Moreover, HCC-specific T-cell responses could be induced by monocytes activated with GM-CSF and incubated with thermally ablated HCC tissue. HCC thermal ablation can create an antigenic source along with stimuli appropriate for maturation of APCs to induce HCC-specific T-cell responses. These results contribute to explain at least in part the adjuvant effect of HCC thermal ablation and suggest a novel strategy to induce maturation of APCs and their loading with HCC antigens for active immunotherapy protocols aimed at reducing HCC recurrence after thermal ablation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18317360     DOI: 10.1097/CJI.0b013e318160ff1c

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  30 in total

Review 1.  Combined locoregional treatment of patients with hepatocellular carcinoma: State of the art.

Authors:  Roberto Iezzi; Maurizio Pompili; Alessandro Posa; Giuseppe Coppola; Antonio Gasbarrini; Lorenzo Bonomo
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

Review 2.  Combined locoregional-immunotherapy for liver cancer.

Authors:  Tim F Greten; Michal Mauda-Havakuk; Bernd Heinrich; Firouzeh Korangy; Bradford J Wood
Journal:  J Hepatol       Date:  2019-02-07       Impact factor: 25.083

3.  Combination of percutaneous radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: observation of clinical effects.

Authors:  Hui-Chun Liu; Er-Bo Shan; Lei Zhou; Hao Jin; Pei-Yuan Cui; Yi Tan; Yi-Min Lu
Journal:  Chin J Cancer Res       Date:  2014-08       Impact factor: 5.087

4.  Radio frequency ablation of renal tumors in patients with metastatic renal cell carcinoma.

Authors:  Jose A Karam; Kamran Ahrar; Christopher G Wood; Eric Jonasch; Raghunandan Vikram; Claudio Romero; Nizar Tannir; Surena F Matin
Journal:  J Urol       Date:  2010-09-17       Impact factor: 7.450

Review 5.  Immunobiology of hepatocellular carcinoma.

Authors:  Tobias Flecken; Hans Christian Spangenberg; Robert Thimme
Journal:  Langenbecks Arch Surg       Date:  2011-04-09       Impact factor: 3.445

6.  Abrogation of local cancer recurrence after radiofrequency ablation by dendritic cell-based hyperthermic tumor vaccine.

Authors:  Qiong Liu; Bo Zhai; Wen Yang; Le-Xing Yu; Wei Dong; Ya-Qin He; Lei Chen; Liang Tang; Yan Lin; Dan-Dan Huang; Hong-Ping Wu; Meng-Chao Wu; He-Xin Yan; Hong-Yang Wang
Journal:  Mol Ther       Date:  2009-09-22       Impact factor: 11.454

7.  Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non-small-cell lung cancer.

Authors:  T Schneider; A Sevko; C P Heussel; L Umansky; P Beckhove; H Dienemann; S Safi; J Utikal; H Hoffmann; V Umansky
Journal:  Clin Exp Immunol       Date:  2015-04-15       Impact factor: 4.330

8.  Combined percutaneous radiofrequency ablation and ethanol injection versus hepatic resection for 2.1-5.0 cm solitary hepatocellular carcinoma: a retrospective comparative multicentre study.

Authors:  Shuling Chen; Zhenwei Peng; Manxia Lin; Zebin Chen; Wenjie Hu; Xiaoyan Xie; LongZhong Liu; Guojun Qian; Baogang Peng; Bin Li; Ming Kuang
Journal:  Eur Radiol       Date:  2018-03-29       Impact factor: 5.315

9.  In situ thermal ablation augments antitumor efficacy of adoptive T cell therapy.

Authors:  Fumito Ito; Trupti D Vardam; Michelle M Appenheimer; Kevin H Eng; Sandra O Gollnick; Jason B Muhitch; Sharon S Evans
Journal:  Int J Hyperthermia       Date:  2019-11       Impact factor: 3.914

10.  Hepatocellular carcinoma from an immunologic perspective.

Authors:  Tim F Greten; Austin G Duffy; Firouzeh Korangy
Journal:  Clin Cancer Res       Date:  2013-09-12       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.